

## Study: ENGOT-gyn2 / BOUQUET

A phase II, open-label, multicentre, platform study evaluating the efficacy and safety of biomarker driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors

### MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	Yes